Received May 6, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Z018832 | — |
No additional AE; HBP calling with a report of an adverse event regarding improperly stored and administered PROQUAD. HBP stated that a dose of PROQUAD was administered on 4/30/2026 after being exposed to multiple temperature excursions. HBP confirmed that their fac; This spontaneous report was received from a consumer or other non-health professional and refers to a patient of unknown age and gender. The patient's concomitant medication, pertinent medical history and drug reactions/allergies were not reported. On 30-Apr-2026, the patient was vaccinated with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), (0.5ml, total; also mentioned two dose series; lot# Z018832,expiration date was reported as 11-Jun-2026, but upon internal validation established as 11-Mar-2027; strength and route of administration were not reported) for prophylaxis. The vaccine was improperly stored and administered, after being exposed to multiple temperature excursions (Product storage issue). The reporter confirmed that their facility had not received any reports of the patient experiencing any medical concerns or reactions at this time (No adverse event). No additional adverse event was reported.